Menopausal hot flushes and sweats affect around 80% of women, can cause significant distress and can last for many years. Hormone Replacement Therapy is recommended as first line treatment, but is not appropriate nor desired by all women with symptoms. This is especially relevant to women who have had hormone dependant cancer. Non hormonal treatments [...]
It has been recognised for many years that more women than men are affected by Alzheimer’s Dementia (AD). Female hormones have been thought to play a role and new information adds more evidence to the debate. A recently published study investigated the differences in brain biomarkers of AD in men and women. (A biomarker is [...]
The British Menopause Society has issued this further update on the current availability of HRT products to provide guidance to BMS members and clinical practitioners in response to the ongoing HRT shortages.
Please see a joint framework statement from the BMS, RCOG, RCGP and FSRH regarding the restoration of menopause services in response to COVID-19.
A Primary Care Women’s Health Forum Webinar on how to manage HRT provision without face to face consultations during COVID-19 healthcare restrictions is taking place on Thursday 4 June 2020 at 7pm
The Primary Care Women’s Health Forum has produced this guide for primary care practitioners in order to provide support for HRT provision during this time.
The British Menopause Society has issued this further update on the current availability of HRT products to provide guidance to BMS members and clinical practitioners in response to the ongoing HRT shortages.
BMS statement on the RCOG/BSGE/BGCS document on the management of irregular menstrual bleeding/postmenopausal bleeding.
A joint statement from the BMS, RCOG, RCGP and FSRH.
FSRH has advised that the use of the Mirena IUS can be extended up to 6 years for contraception.
